Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements & Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Archives
April 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
Categories
Company News
Media
Uncategorized
Videos
13 Feb 2023
Women in Science | Q&A with Dr Terrie-Anne Cock, Head of Translational Biology
Read More
09 Feb 2023
35th Annual Lorne Cancer Conference, 9-11 February 2023
Read More
01 Feb 2023
First Patient Recruited to Cohort 2 of ACCENT Trial in Pancreatic Cancer
Read More
08 Dec 2022
Meet the CEO | Dr Chris Burns
Read More
29 Nov 2022
ACCENT Trial Recruitment Progress
Read More
03 Oct 2022
AMP886 Activity in Acute Myeloid Leukemia (AML)
Read More
18 Aug 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
02 Aug 2022
First patient recruited into ACCENT trial
Read More
28 Jul 2022
QUARTERLY REPORT & 4C
Read More
23 Jun 2022
Navigating human research ethics
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
30 Mar 2022
Amplia is hiring
Read More
17 Feb 2022
Improving Pancreatic Cancer Survival Rates
Read More
11 Feb 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
24 Jan 2022
Quarterly Report & 4C
Read More
02 Dec 2021
$2.1M R&D Cash Flow Loan
Read More
17 Nov 2021
New Phase 1 Clinical Trial Data
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
26 Oct 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
30 Sep 2021
New FAK research published in Science Advances
Read More
1
2
3